Published • loading... • Updated
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
- Rznomics Inc. presented interim Phase 1/2a clinical results for RZ-001, an RNA editing-based gene therapy for recurrent glioblastoma, at ASNO 2026 in Kanazawa, Japan on June 13th.
- The presentation on safety and preliminary efficacy data from the ongoing trial of RZ-001 was delivered by Dr. Chae-Yong Kim.
- The interim analysis showed no new or unexpected treatment-related safety concerns, with no dose-limiting toxicity or Grade 4 or higher adverse events reported.
- Several patients experienced tumor recurrence inhibition and disease control for over six months, with Dr. Kim noting a manageable safety profile and encouraging preliminary clinical activity.
Insights by Ground AI
50 Articles
50 Articles
The Berkshire Eagle+49 Reposted by 49 other sources
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patientsA manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources50
Leaning Left9Leaning Right4Center18Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 29%
C 58%
13%
Factuality
To view factuality data please Upgrade to Premium
